Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
Breast Cancer Published 2 years ago
Content
Breast Cancer
3m 42s
ESR1 Mutation in clinical practice – A snapshot
Published 20 Jul 2022
Breast Cancer is heterogenous disease & ER+ve & Her2 Negative (Luminal) is most common subtype of Breast Cancer. For ER+ve & Her2 Negative patients endocrine therapy remains the most important systemic treatment option. Despite offering all the benefits like improved overall survival, response rates & control of symptoms for months or years, patients eventually develop disease progression attributable to complex mechanisms of endocrine resistance. ESR1 mutation is one of the important mechanism of endocrine resistance. ESR1 mutations are found in 15-40% of all patients who progress on 1st line Aromatase Inhibitor therapy. Presence of ESR 1 mutation is prognostic biomarker associated with aggressive disease associated with inferior survival outcomes.
